Causal associations between plasma proteins and prostate cancer: a Proteome-Wide Mendelian Randomization
Lin Chen, Gu Yanlun, Chen Yuke, Yu Wei, Zhou Ying, Rong Zhuona, Xiaocong PangiD
Abstract
BackgroundDue to the limitations in specificity of current diagnostic methods for prostate cancer (PCa), more reliable biomarkers are needed to explore for improving early detection. Plasma proteins represent a promising source of biomarkers, therefore understanding the causal relationships between specific plasma proteins and PCa could be conductive to identify novel biomarkers and therapeutic targets for PCa prevention and treatment. MethodsWe performed a meta-analysis of two independent genome-wide association studies (GWASs) including 94,397 individuals with PCa and 192,372 controls. A mendelian randomization (MR) supplemented by colocalization analysis was conducted, using cis-acting variants on 4,907 plasma proteins from deCODE Genetics (N=35,559) and 2,940 plasma proteins from UK Biobank Pharma Proteomics Project (UKB-PPP) (N=54,219). Then, the biological pathway analysis and druggability evaluation of the risk proteins were further performed. ResultsFive possible susceptibility loci (JAZF1, PDILM5, WDPCP, EEFSEC, and TNS3) for PCa were identified through the meta-analysis of GWASs. Among 3,722 plasma proteins, 193 proteins were associated with PCa risk, of which 20 high-risk proteins, including KLK3, were validated in both the deCODE and UKB-PPP cohorts. Functional annotation of these genes encoding proteins confirmed enrichment of immune response, inflammatory response, cell-cell interaction and so on. Genetic colocalization and druggable genome analyses also identified several potential drug targets for PCa, such as HSPB1, RRM2B and PSCA. ConclusionsWe identified novel variants as well as several protein biomarkers linked to PCa risk and indicated pathways associated with PCa, which offered new insights into PCa etiology and contributed to development of novel biomarkers for early detection and potential therapeutic interventions. FundingThis work was supported by grants from Beijing Municipal Natural Science Foundation (grant No. JQ24059, No. L234038, No. L248076) and National Natural Science Foundation of China (grant No. 82274015). O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=147 SRC="FIGDIR/small/24312688v2_ufig1.gif" ALT="Figure 1"> View larger version (31K): org.highwire.dtl.DTLVardef@63725dorg.highwire.dtl.DTLVardef@e94c62org.highwire.dtl.DTLVardef@95c2b4org.highwire.dtl.DTLVardef@21f752_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGraphical abstractC_FLOATNO A comprehensive study design summarized as follows. C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 0th percentile
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Identifying therapeutic targets for cancer: 2,094 circulating proteins and risk of nine cancers
Karl Smith-Byrne, Åsa K. Hedman, … Anders Mälarstig·Nature CommunicationsPeer-reviewed·Apr 29, 2024
- Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases
Jie Zheng, Valeriia Haberland, … Tom R. Gaunt·Nature GeneticsPeer-reviewed·Sep 7, 2020
- Uncovering bi-directional causal relationships between plasma proteins and psychiatric disorders: A proteome-wide study and directed network analysis
Carlos Kwan-long Chau, Alexandria Lau, … Hon-Cheong So·bioRxiv·May 18, 2020
- Risk factors for eight common cancers revealed from a phenome-wide Mendelian randomisation analysis of 378,142 cases and 485,715 controls
Molly Went, Amit Sud, … Richard S. Houlston·Nature CommunicationsPeer-reviewed·Mar 25, 2024
- Proteome-by-phenome Mendelian Randomisation detects 38 proteins with causal roles in human diseases and traits
Andrew D. Bretherick, Oriol Canela‐Xandri, … Chris Haley·PLoS GeneticsPeer-reviewed·Jul 6, 2020
- Genetic associations between SGLT2 inhibition, DPP4 inhibition or GLP1R agonism and prostate cancer risk: a two-sample Mendelian randomisation study
Lin Shen, Yifan Yang, … Jiandong Zhou·medRxiv·Sep 15, 2024